TY - JOUR
T1 - Cancer/testis antigens and urological malignancies
AU - Kulkarni, Prakash
AU - Shiraishi, Takumi
AU - Rajagopalan, Krithika
AU - Kim, Robert
AU - Mooney, Steven M.
AU - Getzenberg, Robert H.
N1 - Funding Information:
This work was supported by a National Cancer Institute Specialized Program of Research Excellence, the Bernard L. Schwartz Scholar Award by the Patrick C. Walsh Cancer Research Fund, and the Patana Fund of the Brady Urological Institute.
PY - 2012/7
Y1 - 2012/7
N2 - Cancer/testis antigens (CTAs) are a group of tumour-associated antigens (TAAs) that display normal expression in the adult testisĝ€"an immune-privileged organĝ€"but aberrant expression in several types of cancers, particularly in advanced cancers with stem cell-like characteristics. There has been an explosion in CTA-based research since CTAs were first identified in 1991 and MAGE-1 was shown to elicit an autologous cytotoxic T-lymphocyte (CTL) response in a patient with melanoma. The resulting data have not only highlighted a role for CTAs in tumorigenesis, but have also underscored the translational potential of these antigens for detecting and treating many types of cancers. Studies that have investigated the use of CTAs for the clinical management of urological malignancies indicate that these TAAs have potential roles as novel biomarkers, with increased specificity and sensitivity compared to those currently used in the clinic, and therapeutic targets for cancer immunotherapy. Increasing evidence supports the utilization of these promising tools for urological indications.
AB - Cancer/testis antigens (CTAs) are a group of tumour-associated antigens (TAAs) that display normal expression in the adult testisĝ€"an immune-privileged organĝ€"but aberrant expression in several types of cancers, particularly in advanced cancers with stem cell-like characteristics. There has been an explosion in CTA-based research since CTAs were first identified in 1991 and MAGE-1 was shown to elicit an autologous cytotoxic T-lymphocyte (CTL) response in a patient with melanoma. The resulting data have not only highlighted a role for CTAs in tumorigenesis, but have also underscored the translational potential of these antigens for detecting and treating many types of cancers. Studies that have investigated the use of CTAs for the clinical management of urological malignancies indicate that these TAAs have potential roles as novel biomarkers, with increased specificity and sensitivity compared to those currently used in the clinic, and therapeutic targets for cancer immunotherapy. Increasing evidence supports the utilization of these promising tools for urological indications.
UR - http://www.scopus.com/inward/record.url?scp=84863718471&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863718471&partnerID=8YFLogxK
U2 - 10.1038/nrurol.2012.117
DO - 10.1038/nrurol.2012.117
M3 - Review article
C2 - 22710665
AN - SCOPUS:84863718471
SN - 1759-4812
VL - 9
SP - 386
EP - 396
JO - Nature Reviews Urology
JF - Nature Reviews Urology
IS - 7
ER -